MENLO PARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Intersect ENT (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the Company has been added to the Russell 2000® index, effective as of the close of market today.
Russell indices are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. The Russell 2000 index, a subset of the Russell 3000® index, measures the performance of the small-cap segment of U.S. equity stocks. The index is reconstituted annually to ensure larger stocks do not distort the performance and characteristics of the small-cap opportunity set.
Additional information about the Russell Investments indexes can be found at http://www.russell.com/indexes/americas/default.page.
About Intersect ENT
Intersect ENT (Nasdaq:XENT) is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two drug-eluting implants, PROPEL and PROPEL mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis. In addition, Intersect ENT is developing new drug-eluting implants designed to provide ENT physicians with even more customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers. For more information, please visit www.intersectENT.com.